Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMO | O15229 | 2/20 | 0.34 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.33 |
| ▸ | RXRA | P19793 | 1/20 | 0.30 |
| ▸ | RXRB | P28702 | 1/20 | 0.30 |
| ▸ | RXRG | P48443 | 1/20 | 0.30 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.30 |
| ▸ | ALPL | P05186 | 1/20 | 0.30 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.30 |
| ▸ | GSTO1 | P78417 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8074941 | 0.72 | PDE2A (0.33) | KMOEPHX2 | |
| SCHEMBL28056270 | 0.72 | PDE2A (0.33) | KMOEPHX2 | |
| SCHEMBL30127239 | 0.70 | MPL (0.36) | EPHX2SCN9A | |
| SCHEMBL19485985 | 0.68 | ALDH1A1 (0.35) | — | |
| SCHEMBL16798567 | 0.68 | PDE2A (0.30) | — | |
| SCHEMBL10710521 | 0.68 | EPHX2 (0.37) | KMOEPHX2 | |
| SCHEMBL8488946 | 0.67 | AKR1C2 (0.42) | KMOEPHX2RXRARXRBRXRG | |
| SCHEMBL29721858 | 0.67 | AKR1C2 (0.40) | KMOEPHX2RXRARXRBRXRG | |
| SCHEMBL29917977 | 0.67 | KMO (0.42) | KMOEPHX2RXRARXRBRXRG | |
| SCHEMBL29006785 | 0.67 | AKR1C2 (0.40) | KMOEPHX2RXRARXRBRXRG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1794164-A2 | BRIDGED PIPERAZINE AND PIPERIDINE DERIVATIVES AS CCR1 ANTAGONISTS | Novartis AG (CH) | 2007-06-13 | — | — | EP | disclosed |
| WO-2005103054-A2 | BRIDGED PIPERAZINE AND PIPERIDINE DERIVATIVES AS CCRI ANTAGONISTS | NOVARTIS AG (CH) | 2005-11-03 | — | — | WO | disclosed |